Description
The Naveni® PD1/PD-L1 BOND RX Red is an in situ proximity ligation assay kit for the detection of the interaction of PD1 and PD-L1 using BOND RX/RXm Fully Automated Research Stainer. The kit has been validated on FFPE human tissue samples.
Not recommend for mouse tissue. For research use only. Not for use in diagnostic procedures.
The kit is based on the Naveni® in situ proximity ligation technology with automated workflow. It uses two Navenibodies linked to proprietary oligo arms. The primary antibodies included in the kit bind to PD1 and PD-L1 proteins, while Navenibodies then bind to their respective primary antibodies. When Navenibodies are in close proximity, a strong and distinct signal is generated, offering a specific and sensitive detection method for the interaction between PD1 and PD-L1. Read more about the automated technology here.
Product code: 60012
Included in the Naveni® PD1/PD-L1 BOND RX Red kit:
- Navenibody targeting human PD1 protein based on clone EH33 CST
- Navenibody targeting human PD-L1 protein based on clone SP142 Abcam RabMAb®
- Buffers for blocking and dilutions and detection reagents for the PD1/PD-L1 interaction signal
- Reagents sufficient for 30 FFPE tissue slides, including dead volumes
Required Materials and Reagents to run Naveni PD1/PD-L1 BOND RX Red:
These materials are not included in the kit and must be purchased separately.
| Leica, Cat # | Description |
|---|---|
| OPT9049 | BOND titration kit (6ml) |
| DS9455
(DS9777) |
BOND Research Detection System
(BOND Research Detection System 2) |
| S21.4611 | BOND Universal Covertiles |
| S21.0304 | Slide Tray |
| S21.1003 | Reagent Tray |
| S21.4564 | Slide Labels and Printer Ribbon |
| AR9222 | BOND Dewax Solution |
| AR9961 | BOND Epitope Retrieval Solution 1 |
| AR9640 | BOND Epitope Retrieval Solution 2 |
| AR9590 | BOND Wash Solution 10X Concentrate |
| CS9100 | BOND Aspirating Probe Cleaning Kit |
| Laboratory Materials | Vendor, Cat# |
|---|---|
| Mounting medium for fluorescent dyes | Sigma-Aldrich, F6182* |
| Coverslip for microscope slides | |
| DAPI (diluted in PBS to 1 µg/mL)** | Thermo Fisher Scientific, 62248 |
| Deionized water | |
| Reagent Grade Alcohol | Refer to the BOND RX 7.0 User Manual |
| TBS-T (T=Tween) |
*Fluoroshield mounting medium or any mounting medium compatible with fluorescent dyes.
**It is possible to exclude the DAPI staining step in the instrument stain with DAPI off-board.
Software requirements to run Naveni PD1/PD-L1 BOND RX
- BOND RX v7.0 software
- BXD 40
Documents
- Instructions for use Naveni PD1 PD-L1 BOND RX Red (PDF)
- Product Sheet Naveni PD1 PD-L1 BOND RX Red (PDF)
- SDS (PDF)
- Leica Biosystems BOND RX Brochure (PDF)
- FAQ
Find better prognostic biomarkers
PD1/PD-L1 signaling, in combination with immune checkpoint inhibitors, has proven to play a critical role in both cancer progression and treatment. Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear.
Naveni® PPI
Proteins perform a wide range of functions and are the closest way to understand biology. Proteins are also key targets in both health and disease. When proteins carry out their function, they interact with other proteins or molecules. To understand biological pathways and mode of action, we need to get a deeper insight into protein functions and how the protein interacts. Detecting the interactions has until now been either complicated, unspecific, or insensitive. The Naveni® in situ proximity ligation technology enables visualization of protein-protein interaction using one primary antibody for each target protein, without the need to disrupt the tissue microenvironment.
Keywords: Proximity Ligation Assay, protein-protein interaction (PPI), in situ, bright-field, chromogenic, immunohistochemistry, western blot, validated antibodies, Immuno-oncology, immunotherapy, patient stratification, biomarker, drug-target engagement, tissue microenvironment, single-cell resolution, BRET, FRET, Co-IP.